Ankita Sahu

Dr. Ankita Sahu

Institute of Genomics and Integrative Biology, Delhi, India
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
LGLiam Goldman
Liam Goldman
ESEhraz Mehmood Siddiqui
Ehraz Mehmood Siddiqui
Andleeb KhanAndleeb Khan
Andleeb Khan
Sadaf JahanSadaf Jahan
Sadaf Jahan
MRMuneeb U Rehman
Muneeb U Rehman
Kumar VaibhavKumar Vaibhav
Kumar Vaibhav
Any type of brain injury that transpires post-birth is referred to as Acquired Brain Injury (ABI). In general, ABI does not result from congenital disorders, degenerative diseases, or by brain trauma at birth. Although the human brain is protected from the external world by layers of tissues and bone, floating in nutrient-rich cerebrospinal fluid (CSF); it remains susceptible to harm and impairment. Brain damage resulting from ABI leads to changes in the normal neuronal tissue activity and/or structure in one or multiple areas of the brain, which can often affect normal brain functions. Impairment sustained from an ABI can last anywhere from days to a lifetime depending on the severity of the injury; however, many patients face trouble integrating themselves back into the community due to possible psychological and physiological outcomes. In this review, we discuss ABI pathologies, their types, and cellular mechanisms and summarize the therapeutic approaches for a better understanding of the subject and to create awareness among the public.

1 March 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MRManish Rana
Manish Rana
RARizwan Arif
Rizwan Arif
Faez Iqbal KhanFaez Iqbal Khan
Faez Iqbal Khan
VMVikas Maurya
Vikas Maurya
RSRaja Singh
Raja Singh
RARahisuddin
Rahisuddin

28 March 2023 in WIREs Mechanisms of Disease
Verified
Journal Article
Open access
ASAnkita Sahu
Ankita Sahu
KRKhalid Raza
Khalid Raza
DPDibyabhaba Pradhan
Dibyabhaba Pradhan
AJArun Kumar Jain
Arun Kumar Jain
SVSaurabh Verma
Saurabh Verma
Cyclooxygenase‐2 (COX‐2) is a key aspect of the physiology and pathogenesis of various cancer types. Overexpression of this enzyme is responsible for the elevated prostaglandin production and characteristic feature of breast cancer. Inhibition of COX‐2 derived prostanoids facilitates anti‐inflammatory, analgesic, and antipyretic effects of non‐steroid anti‐inflammation drugs. The overexpression of COX‐2 is associated with inflammation, pain, and fever. The present study provides the updated relevant literature describing the role of well‐characterized isoforms of cyclooxygenase with particular emphasis on COX‐2, mechanism of action, the effect of the drug, combinatorial drugs, and microarray‐based differential expression analysis and network analysis. We have discussed the currently used combinatorial treatments and their challenges in breast cancer.This article is categorized under: Cancer > Computational Models Cancer > Molecular and Cellular Physiology

2 October 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAnkita Sahu
Ankita Sahu
Shaban AhmadShaban Ahmad
Shaban Ahmad
KIKhalid Imtiyaz
Khalid Imtiyaz
AKAjeeshkumar Kizhakkeppurath Kumaran
Ajeeshkumar Kizhakkeppurath Kumaran
MIMojahidul Islam
Mojahidul Islam
SVSaurabh Varma
Saurabh Varma
Aromatase enzyme plays a fundamental role in the development of estrogen receptors, and due to this functionality, the enzyme has gained significant attention as a therapeutic for reproductive disorders and cancer diseases. The currently employed aromatase inhibitors have severe side effects whereas our novel aromatase inhibitor is more selective and less toxic, therefore has greater potential to be developed as a drug. The research framework of this study is to identify a potent inhibitor for the aromatase target by profiling molecular descriptors of the ligand and to find a functional pocket in the target by docking and MD simulations. For assessing cellular and metabolic activities as indicators of cell viability and cytotoxicity, in-vitro studies were performed by using the colorimetric MTT assay. Aromatase activities were determined by a fluorometric method. Cell morphology was assessed by phase-contrast light microscopy. Flow cytometry and Annexin V-FITC/PI staining assay determined cell cycle distribution and apoptosis. This study reports that CHEMBL708 (Ziprasidone) is the most promising compound that showed excellent aromatase inhibitory activity. By using better drug design methods and experimental studies, our study identified a novel compound that could be effective as a high-potential drug candidate against aromatase enzyme. We conclude that the compound ziprasidone effectively blocks the cell cycle at the G1-S phase and induces cancer cell death. Further, in-vivo studies are vital for developing ziprasidone as an anticancer agent. Lastly, our research outcomes based on the results of the in-silico experiments may pave the way for identifying effective drug candidates for therapeutic use in breast cancer.

3 July 2017 in Journal of Receptors and Signal Transduction
Verified
Journal Article
Closed access
ASAnkita Sahu
Ankita Sahu
PPP. K. Patra
P. K. Patra
MYManoj Kumar Yadav
Manoj Kumar Yadav
MVMeena Varma
Meena Varma
The overexpression of ErbB4 is associated with aggressive disease biology and reduced the survival of breast cancer patients. We have used ErbB4 receptor as a novel drug target to spearhead the rational drug design. The present study is divided into two parts. In the first part, we have exploited the hidden information inside ErbB4 kinase receptor both at sequence and structural level. PSI-BLAST algorithm is used to search similar sequences against ErbB4 kinase sequence. Top 15 sequences with high identity were selected for finding conserved and variable regions among sequences using multiple sequence alignment. In the second part, available 3 D structure of ErbB4 kinase is curated using loop modeling, and anomalies in the modeled structure is improved by energy minimization. The resultant structure is validated by analyzing dihedral angles by Ramachandran plot analysis. Furthermore, the potential binding sites were detected by using DoGSite and CASTp server. The similarity-search criterion is used for the preparation of our in-house database of drugs from DrugBank database. In total, 409 drugs yet to be tested against ErbB4 kinase is used for screening purpose. Virtual screening results in identification of 11 compounds with better binding affinity than lapatinib and canertinib. Study of protein–ligand interactions reveals information about amino acid residues; Lys726, Thr771, Met774, Cys778, Arg822, Thr835, Asp836 and Phe837 at the binding pocket. The physicochemical properties and bioactivity score calculation of selected compounds suggest them as biological active. This study presents a rich array that assist in expediting new drug discovery for breast cancer.

2 March 2022
Verified
Book Chapter
Closed access
PDF file
ASAnkita Sahu
Ankita Sahu
SQSahar Qazi
Sahar Qazi
KRKhalid Raza
Khalid Raza
ASAstha Singh
Astha Singh
SVSaurabh Verma
Saurabh Verma